• Proteomics R&D
• Proteomics Partnering
• Genomics R&D
• Recent Publications
• Pharmacogenomics Partnering

Cancer Discovery via Proteomics

Identification of cell surface antigens associated with cancer for use in therapeutic antibody and small molecule drug development as well as diagnostics 51 targets fully validated; 184 additional proteins selected for validation status Gene expression would predict only 20% of our proteomic targets

Celera is building a product portfolio based on its expertise in proteomics and genomics by identifying and validating differentially expressed proteins on the surface of cancer cells. Proteins that are over-expressed on diseased cells relative to healthy cells may represent targets for therapeutic antibodies or small molecule drugs. Celera is working with its current therapeutic partners Abbott Laboratories, Seattle Genetics, and Genentech to advance therapies into validation and development against Celera's targets.

Celera is currently producing a significant number of validated targets each year from its protein therapeutic discovery platform. Our current efforts are focused on a variety of oncology indications, but the platform is transferable to diabetes, obesity, and variety of other disease areas. We are actively seeking therapeutic partners for our targets and offer great flexibility in our collaboration structures:

To discuss partnering opportunities around our Proteomics platform, please contact: Alliance.Management@celera.com